Outcome of Second Allogeneic Hematopoietic Cell Transplantation after Relapse of Myeloid Malignancies following Allogeneic Hematopoietic Cell Transplantation: A Retrospective Cohort on Behalf of the Grupo Español de Trasplante Hematopoyetico
详细信息 查看全文
- 作者：Guillermo Orti1 ; g.ortivh@gmail.com" class="auth_mail" title="E-mail the corresponding author ; Jaime Sanz1 ; Arancha Bermudez1 ; Dolores Caballero1 ; Carmen Martinez1 ; Jorge Sierra1 ; José ; R. Cabrera Marin1 ; Ildefonso Espigado1 ; Carlos Solano1 ; Christelle Ferrà ; 1 ; Ana Garcí ; a-Noblejas1 ; Santiago Jimenez1 ; Antonia Sampol1 ; Lucrecia Yañ ; ez1 ; Valentin Garcí ; a-Gutié ; rrez1 ; Maria Jesus Pascual1 ; Manuel Jurado1 ; José ; M. Moraleda1 ; David Valcarcel1 ; Miguel A. Sanz1 ; Enric Carreras1 ; 2 ; Rafael F. Duarte1
- 关键词：Second allogeneic stem cell transplantation ; Relapse ; Acute myeloid leukemia ; Myeloid malignancies
- 刊名：Biology of Blood and Marrow Transplantation
- 出版年：2016
- 出版时间：March 2016
- 年：2016
- 卷：22
- 期：3
- 页码：584-588
- 全文大小：178 K
文摘
- •
Second allogeneic transplantation for myeloid malignancies is feasible for a group of patients.
- •
Active disease and time from first transplantation (<430 days) are associated to a poor outcome
- •
Using a different donor at second allogeneic transplantation did not appear to change outcome
- •
The use of an HLA-identical sibling donor at second allogeneic hematopoietic cell transplantation appears to be associated with better survival